Progenity, a US-based pharmaceutical company, has acquired life sciences firm Carmenta Bioscience 18 months after it spun out of Stanford University.
As part of the deal, Carmenta’s CEO Matthew Cooper will join Progenity as chief scientific officer. Other terms, including acquisition price, were not disclosed.
Carmenta has been developing a protein-based test for preeclampsia, a hypertensive disorder of pregnancy. The condition is a leading cause of foetal deaths, and affects up to 8% of pregnant women.
